Peptide dendrimer (APNPs core)
Sequence: (H-Cys-SH)2-Lys-Glu(G2) peptide dendrimer (compound 6)
| Experiment Id | EXP000153 |
|---|---|
| Paper | A tumor-activatable peptide supramolecular nanoplatform for the delivery of dual-gene targeted siRNA |
| Peptide | Peptide dendrimer (APNPs core) |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | 200 µg siRNA/kg |
| Rna Concentration | hTERT + TRF2 siRNA (1:1) |
| Mixing Ratio | NPs:siRNA = 15:1 (w/w) |
| Formulation Format | Peptide dendrimer supramolecular nanoparticle (APNPs–siRNA) |
| Formulation Components | ~121 nm (circulation) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | A549/PTX drug-resistant xenograft nude mouse |
| Administration Route | IV (tail vein) |
| Output Type | tumor growth inhibition / anti-angiogenesis |
| Output Value | ~76% tumor growth inhibition; reduced Ki67 and CD31 |
| Output Units | |
| Output Notes | |
| Toxicity Notes | No significant weight loss or organ toxicity |
| Curation Notes |